



Fig. S1. Efficacy and safety of hBMSC in CKD rat model according to injection route and hBMSC dose. RA, renal artery; RA-C, renal artery control; RA-LD, renal artery low dose; RA-MD, renal artery moderate dose; RA-HD, renal artery high dose; TV-C, tail vein control; TV-LD, tail vein low dose; TV-MD, tail vein moderate dose; TV-HD, tail vein high dose. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$, vs. the RA-C group; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$, vs. the TV-C group. Red colored stars indicate statistically significant differences in RA-LD, RA-MD, RA-HD, groups compared to the RA-C group, respectively. Blue colored stars indicate statistically significant differences in TV-LD, TV-MD, TV-HD, groups compared to the TV-C group, respectively. (A~D) 3 times per rat, 10 rats per group, but 9 rats in the RA-C, TV-LD, TV-HD groups and 8 rats in the TV-MD groups. (E~H) 1 times per rat, 10 rats per group, but 9 rats in the RA-C, TV-LD, TV-HD groups and 8 rats in the TV-MD groups.